Biogen Inc. (BIIB)

Healthcare
$200.05▲ 0.09 (0.05%)
Real-time prices · US Markets
📅
Next earnings: Jul 30
Bullish
7.5 / 10
Clean balance sheet with low leverage (0.4× debt-to-equity).
Quality
7
Health
9.7
Growth
7.8
Valuation
6.4
Sentiment
6.7
Analyst Target
$220.63
▲ +10.3% from current

Price Chart

Fundamentals

Trailing P/E
21.5×
price-to-earnings
Forward P/E
12.0×
next 12 months est.
Market Cap
$29.5B
market capitalization
Div Yield
dividend yield
Profit Margin
13.8%
net profit margin
Gross Margin
78.7%
revenue minus COGS
ROE
7.7%
return on equity
Beta
0.18
vs S&P 500
52-Week Range
$121 — $206
annual min — max

EPS — Estimate vs Actual

Frequently Asked Questions

What do analysts say about Biogen Inc. right now?
Biogen Inc.'s Q·Score is 7.5/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for BIIB?
The consensus price target for BIIB is $220.63, based on ratings from 30 Wall Street analysts. This is 10.3% above the current price of $200.05. Price targets are forward-looking estimates and not guarantees of future performance.
Is BIIB overvalued or undervalued?
Biogen Inc. (BIIB) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 12.0×. The consensus analyst price target of $220.63 is 10% above the current price.
When does Biogen Inc. report its next earnings?
Biogen Inc.'s next earnings report is expected on approximately July 30, 2026.
What is Biogen Inc.'s profit margin?
Biogen Inc. has a net profit margin of 13.8%, which is solid for most industries. Its gross margin stands at 78.7%, indicating a high-margin business model.
Is Biogen Inc.'s revenue growing?
Biogen Inc. is reporting modest revenue growth of 1.9%. Earnings are also growing at 31.1%, indicating improving profitability.
How much debt does Biogen Inc. have?
Biogen Inc. has a debt-to-equity ratio of 0.35×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 3.06×, indicating comfortable short-term liquidity.
Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026